

Response
0.24
0.22
0.20
0.18
0.16
0.14
0.12
0.10
0.08
0.06
0.04
Half Antibody Molecule
15A7H
h15A7
3
14
5
6
7
8
9
10
11
12
13
14
15
16
Time [min]

FIG. 1




15A7H Data
15A7H Fit
IgG4 Data
IgG4 Fit
MFI
70000
60000
50000
40000
30000
20000
10000
0
0.001
0.1
10
conc µg/ml

FIG.2

FIG. 3


n=4 donors
% inhibition of footpad thickness
0
20
40
60
80
100
V
0.03
0.1
0.3
1
10
-36%
-48%
-61%
-79%
-91%
*
*
*
15A7H (mpk i.p.)
* p<0.05 ANOVA



n= 4 donors
15A7H
ED50: 770ng/ml (~ 0.1mpk)
PD: % inhibition of DTH
PK: 15A7H ng/ml
110
100
90
80
70
60
50
40
30
20
10
0
10
100
1000
10000
100000

FIG. 4



15A7H plasma concentration (ng/mL)
100000
10000
1000
100
10
0
4
8
12
16
20
24
Time after dosing (h)
10 mg/kg
1 mg/kg
0.3 mg/kg
0.1 mg/kg
0.03 m/gkg
Satellite PK mice
DTH mice

FIG. 5



CDC with Ramos Cells and Rabbit Complement
Percent Cytotoxicity
80
70
60
50
40
30
20
10
0
-10
0.0001
0.001
0.01
0.1
1
10
Antibody Concentration (ug/mL)
Ms Anti-CD20
Hu Kappa IgG4
15A7H

Fig. 6

A. Heavy Chain

```
      {(Variable Region)  FR1            CDR1        FR2
  1   EVQLVESGGG LVQPGGSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAY
          CDR2                          FR3
 51   INGGSSTIFY ANAVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCARYA
       CDR3      FR4      }{
101   SYGGGAMDYW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK

151   DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT
                          (Hinge Region)
201   YTCNVDHKPS NTKVDKRV ES KYGPPCPPCP A PEFLGGPSV FLFPPKPKDT
                       (Constant Region)
251   LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY

301   RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT

351   LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
                                                          }
401   DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK
```

B. Light Chain

```
      {     FR1  (Variable Region)     CDR1          FR2
  1   DIQMTQSPSS LSASVGDRVT ITCRSSQSIV HNDGNTYFEW YQQKPGKAPK
          CDR2                  FR3                  CDR3
 51   LLIYKVSNRF SGVPSRFSGS GSGTHFTLTI SSLQPEDFAT YYCFQGSYVP
        FR4     }{
101   LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK
                       (Constant Region)
151   VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE
                          }
201   VTHQGLSSPV TKSFNRGEC
```

FIG. 7A – 7B